VIVO · Insider Trading
VivoPower PLC Class A Ordinary Shares
Every open-market purchase and sale reported by VIVO officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2023-01-31 | John P. Kenny | Chief Executive Officer | MIXED | −220,591 | — |
| 2023-01-31 | Felicia Williams | Director | D | −10,274 | — |
| 2023-01-31 | Lourdes Weltzien | Executive VP, Life Science | MIXED | −78,100 | — |
| 2023-01-31 | Catherine Sazdanoff | Director | D | −16,424 | — |
| 2023-01-31 | Anthony P Bihl III | Director | D | −15,408 | — |
| 2023-01-31 | Tony Serafini-Lamanna | Executive VP-Diagnostics | MIXED | −35,393 | — |
| 2023-01-31 | Julie Diana Smith | Sr VP, Controller, PAO | MIXED | −55,660 | — |
| 2023-01-31 | Andrew S. Kitzmiller | Executive Vice President & CFO | MIXED | −11,528 | — |
| 2023-01-31 | John McCune Rice Jr. | Director | D | −27,449 | — |
| 2023-01-31 | John McIlwraith | Director | D | −21,724 | — |
| 2023-01-31 | James M. Anderson | Director | D | −33,224 | — |
| 2023-01-31 | Dwight E Ellingwood | Director | D | −17,290 | — |
| 2023-01-09 | James M. Anderson | Director | M | +8,500 | +$173.23K |
| 2022-12-07 | Julie Diana Smith | Sr VP, Controller, PAO | F | −374 | −$11.86K |
| 2022-11-17 | Lourdes Weltzien | EVP, Life Science | F | −4,382 | −$139.48K |
| 2022-11-17 | Tony Serafini-Lamanna | Executive VP-Diagnostics | F | −3,666 | −$116.69K |
| 2022-11-17 | Julie Diana Smith | Sr VP, Controller, PAO | F | −1,845 | −$58.73K |
| 2022-11-08 | John P. Kenny | Chief Executive Officer | F | −4,271 | −$136.71K |
| 2022-11-08 | Tony Serafini-Lamanna | Executive VP-Diagnostics | F | −788 | −$25.22K |
| 2022-11-08 | Julie Diana Smith | Sr VP, Controller, PAO | F | −397 | −$12.71K |
| 2022-11-08 | Lourdes Weltzien | EVP, Life Science | F | −566 | −$18.12K |
| 2022-10-05 | Tony Serafini-Lamanna | Executive VP-Diagnostics | F | −357 | −$11.47K |
| 2022-10-05 | John P. Kenny | Chief Executive Officer | F | −40,269 | −$1.27M |
| 2022-10-05 | Julie Diana Smith | Sr VP, Controller, PAO | F | −360 | −$11.57K |
| 2022-06-28 | John P. Kenny | Chief Executive Officer | MIXED | — | −$1.52M |
| 2022-06-24 | John P. Kenny | Chief Executive Officer | MIXED | — | −$1.05M |
| 2022-02-28 | Andrew S. Kitzmiller | EVP & CFO | Buy | +4,028 | +$100.17K |
| 2022-02-22 | Andrew S. Kitzmiller | EVP & CFO | A | +7,500 | — |
| 2022-02-17 | Lourdes Weltzien | EVP, Life Science | MIXED | — | −$221.54K |
| 2022-01-28 | Felicia Williams | Director | A | +3,012 | — |
| 2022-01-28 | John McCune Rice Jr. | Director | A | +3,012 | — |
| 2022-01-28 | John McIlwraith | Director | A | +3,012 | — |
| 2022-01-28 | Anthony P Bihl III | Director | A | +3,012 | — |
| 2022-01-28 | Catherine Sazdanoff | Director | A | +3,012 | — |
| 2022-01-28 | James M. Anderson | Director | A | +3,012 | — |
| 2022-01-28 | Dwight E Ellingwood | Director | A | +3,012 | — |
| 2022-01-14 | David Phillips | Director | M | +7,500 | +$139.05K |
| 2021-12-22 | Bryan T Baldasare | Exec VP & CFO | F | −1,985 | −$35.57K |
| 2021-12-22 | Lourdes Weltzien | EVP, Life Science | F | −320 | −$5.73K |
| 2021-12-16 | Lourdes Weltzien | EVP, Life Science | F | −4,269 | −$86.06K |
| 2021-12-16 | Tony Serafini-Lamanna | Executive VP-Diagnostics | F | −2,232 | −$45.00K |
| 2021-12-16 | Bryan T Baldasare | Exec VP & CFO | F | −3,807 | −$76.75K |
| 2021-11-16 | Bryan T Baldasare | Exec VP & CFO | MIXED | — | — |
| 2021-11-16 | Tony Serafini-Lamanna | Executive VP-Diagnostics | MIXED | — | — |
| 2021-11-16 | John P. Kenny | Chief Executive Officer | MIXED | — | — |
| 2021-11-16 | Lourdes Weltzien | EVP, Life Science | MIXED | — | — |
| 2021-11-08 | Lourdes Weltzien | EVP, Life Science | A | +10,593 | — |
| 2021-11-08 | John P. Kenny | Chief Executive Officer | A | +56,472 | — |
| 2021-11-08 | Tony Serafini-Lamanna | Executive VP-Diagnostics | A | +10,593 | — |
| 2021-11-08 | Bryan T Baldasare | Exec VP & CFO | A | +10,593 | — |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the VIVO quote page; the site-wide leaderboard is on the insider transactions hub.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.